William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating on July 22.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sami Corwin has given his Buy rating due to a combination of factors that highlight Crispr Therapeutics AG’s promising prospects. The company, in collaboration with Vertex, has successfully launched Casgevy for sickle cell disease and transfusion-dependent β-thalassemia, achieving significant milestones such as activating over 75 authorized treatment centers globally and securing reimbursement agreements in 10 countries. This has led to a substantial number of patient referrals and treatments, resulting in impressive revenue growth.
Additionally, Crispr Therapeutics is expanding its clinical pipeline beyond “one and done” therapies. The initiation of a Phase 2 trial for SRSD107 in collaboration with Sirius Therapeutics, along with planned updates on other promising assets like CTX310 and CTX320, underscores the company’s commitment to advancing its therapeutic offerings. These developments, coupled with anticipated updates on CTX112 for treating CD19-positive r/r B-cell malignancies and autoimmune diseases, reinforce the positive outlook for Crispr Therapeutics, justifying the Buy rating.
In another report released on July 22, Bank of America Securities also reiterated a Buy rating on the stock with a $78.00 price target.